At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 10 enrolled
Drug / intervention
18F-EF5 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Reproducibility of Intratumor Distribution of 18F-EF5 in Head and Neck Cancer
In Brief
A Phase 2 clinical trial evaluating 18F-EF5 and Pretreatment PET/CT-scan (performed two times) for Squamous Cell Carcinoma of the Head and Neck. Completed, enrolled 10 participants across 1 site.
Detailed Summary
The results of previous studies suggest further development of \[18F\]EF5 as a PET tracer for imaging hypoxia. This is a non-randomized prospective study to obtain information on reproducibility of \[18F\]EF5 intratumor distribution using repeated pretreatment PET/CT scans.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesFinland
Collaborators--
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJan 2013
Enrollment StartMar 2013
Primary CompletionSep 2016
TodayJul 2026
First PostedJan 24, 2013
Enrollment StartMar 1, 2013
Primary CompletionSep 1, 2016
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 13.4 years ago
Interventions
18F-EF5drug
Pretreatment PET/CT-scan (performed two times)procedure